Home » Topics » Regulatory » EMA

EMA
RSS

EMA issues positive opinion for orphan status of AEZS-108 in ovarian cancer

May 19, 2010

CHMP adopts positive opinion for variation to terms of Reyataz marketing authorization

April 28, 2010

CHMP recommends conditional marketing approval for Votrient

April 27, 2010

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

April 27, 2010

EMA's CHMP recommends extending indication of tocilizumab

April 27, 2010

EMA's COMP notifies CytRX of positive opinion on bafetinib in CML

April 22, 2010

EMA recommends Cell Therapeutics submit revised PIP for pixantrone

April 22, 2010

European Joulferon MAA for chronic hepatitis C withdrawn

April 21, 2010

Aeterna Zentaris receives advice from the EMA for phase III perifosine program

April 16, 2010

Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context

April 13, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...